In Part II of GEN Edge's exclusive interview, Agilent Technologies CEO Mike McMullen discusses the company's Diagnostics and Genomics Group (DGG), some key factors in DGG’s growth, and potential headwinds to the company’s growth in FY 2022.
Agilent Names John Palma to Lead Global Medical Affairs Organization - read this article along with other careers information, tips and advice on BioSpace
PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying TNBC patients for treatment with KEYTRUDA (pembrolizumab) in Europe. Agilent Technologies Inc. (NYSE: A) today announced that its
SANTA CLARA (dpa-AFX) - Agilent Technologies Inc. (A) has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative
SANTA CLARA (dpa-AFX) - Agilent Technologies Inc. (A) Wednesday said that the U.S. Food and Drug Administration approved its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) as an aid in identifying patients